&w=3840&q=100)
Smallcap stock surges 15%, hits record high today; what's behind the rally?
Shares of Suven Life Sciences (Suven) hit a record high of ₹175, surging 15 per cent on the BSE in Tuesday's intraday trade amid heavy volumes, in an otherwise weak market. The stock price of the smallcap company surpassed its previous high of ₹169, which it touched on September 18, 2024.
In past one week, the market price of Suven Life share appreciated 37 per cent after the company announced a fundraising plan by way of issue of equity shares / warrants / any convertible securities / any other securities, through one or more of the permissible modes including but not limited to a qualified institutions placement, preferential allotment etc.
At 01:34 PM, Suven share price was quoting 10.5 per cent higher at ₹168.80, as compared to 1.5 per cent decline in the BSE Sensex. Average trading volume on the counter jumped six-fold today with 7.3 million equity shares, cumulatively, changing hands on the NSE and BSE till the time of writing this report.
The board of directors of Suven Life Sciences, today, approved fund raising of ₹857.64 crore through fully convertible warrants on preferential basis to continue the funding of R&D, Clinical Development programmes, general corporate purposes, and apex for creating a new R&D facility.
The board of directors of Suven Life Sciences, in its meeting on May 13, 2025, approved the issue of 64 million warrants convertible into equity shares of the company on preferential basis to promoter group entity and to certain non-promoter persons/entities at a price of ₹134 per warrant aggregating up to ₹857.64 crore.
The board approved allotment of 31.77 million warrants to promoter group entity i.e. Jasti Property and Equity Holdings Private Limited (In its capacity as sole trustee of Jasti Family Trust).
The board also approved allotment of warrants to Quant Mutual Fund (4.7 million), Abakkus Diversified Alpha Fund (2.99 million), 3P India Equity Fund 1 (3.36 million), Nilesh Kishor Shah (1.2 million) and Ketan Chhotalal Seth (2 million).
Suven Life Q4 results 2025
Suven Life reported a consolidated loss of ₹44.51 crore for the quarter ended March 2025 (Q4FY25), as against a loss of ₹26.74 crore in the year-ago quarter. Revenue for the quarter stood at ₹2.69 crore, as against ₹6.67 crore in Q4FY24.
The company said the statement of operations includes financials of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.
Suven continues its R&D programs focused on Central Nervous System (CNS) disease disorders and granted 20 patents during the period covering countries Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa and USA
Clinical development pipeline
SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer's type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of FY26.
SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy in Q2FY26.
SUVN-911 (Ropanicant) – Phase 2A open label study for Major Depressive Disorder in the USA successfully completed. The initiated Phase 2B clinical study is in Q1FY26.
SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during FY26.
SUVN-I6107 – Phase 1 study initiated during FY25 is continuing for establishing safety and pharmacokinetics of the molecule.
About Suven Life Sciences
Suven, a Biopharmaceutical company, is engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
The company has a portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), sleep disorders, major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
2 hours ago
- Mint
United Spirits Q1 profit slips 14 pc to ₹417 cr; revenue at ₹6,295 cr
New Delhi, Aug 13 (PTI) Diageo-controlled liquor maker United Spirits Ltd on Wednesday reported a 14 per cent decline in its consolidated net profit to ₹ 417 crore for the June quarter of FY26. The company had posted a net profit of ₹ 485 crore a year ago, according to a regulatory filing from United Spirits Ltd (USL). Its revenue from operations was marginally up at ₹ 6,295 crore during the quarter under review. It was ₹ 6,238 crore in the corresponding period of the previous fiscal. USL's total expenses stood at ₹ 5,776 crore, up 2.79 per cent in the June quarter. In the June quarter, "EBITDA was ₹ 644 crore, down 9.7 per cent, largely due to a one-off indirect tax item impact and relatively higher A&P in the standalone business", said USL in its earnings statement. In the June quarter, USL's income from the 'Beverage alcohol' segment rose 8.37 per cent to ₹ 2,549 crore. Its sports business, Royal Challengers Sports Private Ltd (RCSPL), which owns the RCB team for IPL and WPL, registered a 15.73 per cent growth in revenue to ₹ 478 crore in the June quarter. During the quarter, USL's consolidated net sales value (NSV) rose 9.4 per cent to ₹ 3,021 crore. "This was driven by the 8.4 per cent growth in the standalone business and 15.7 per cent reported growth of the sports business housed in the 100 per cent subsidiary RCSPL," it said. The Prestige & Above segment accounted for 88.3 per cent of net sales during the first quarter. The Popular segment accounted for 9.8 per cent of the net sales during the first quarter. The Popular segment net sales grew 13.6 per cent, it said. Its total income of USL, which owns brands like McDowell's, Royal Challenge, Signature, Johnnie Walker, and Black Dog in its fold, was ₹ 6,367 crore, up 1.5 per cent. "We delivered a resilient quarter with the Prestige & Above portfolio sustaining its growth momentum, while cycling a high prior year base. The quarter also marked the completion of the Nao Spirits acquisition. "Looking ahead, we remain focused on our circle of control to lead the next wave of category growth through sharper portfolio, tailored consumer engagement and revenue growth management," its Managing Director and CEO Praveen Someshwar said. Shares of United Spirits Ltd settled at ₹ 1,306.80 apiece on BSE on Wednesday, up 0.71 per cent from the previous close.
Time of India
2 hours ago
- Time of India
Max Healthcare to nearly double capacity to 9,500 beds by 2028 after strong quarterly growth
Max Healthcare Institute, India's largest healthcare chain by market cap, plans to nearly double its bed capacity to 9,500 in the next three years, Abhay Soi, chairman & managing director, told ET in an interaction on Wednesday. 'We increased our bed capacity by 35% from last year to 5,000. In the next 60 days, we will increase it to 6,000 through brownfield expansion. By 2028, it will go up to about 9,500,' said Soi. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program The company reported a 27% year-on-year growth in first quarter revenue to Rs 2,574 crore, led by an increase in occupied bed days (OBDs). Net profit for the quarter jumped 17% to Rs 345 crore, driven by higher occupancy and international patient inflow. Bed occupancy for the quarter was at 76%, with OBDs up by 26%. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Cardiologist Reveals: The Simple Morning Habit for a Flatter Belly After 50! Lulutox Undo Operating EBITDA rose 23% to Rs 613 crore, with margins at 24.9%. International patient revenue climbed 32% to Rs 208 crore, contributing about 9% of hospital revenue. During the quarter, the company completed a 160-bed tower at its Mohali hospital, signed a lease for a new 130-bed facility in Dehradun and agreed to sell two smaller hospitals in Bulandshahr and Anoopshahr for Rs 40 crore as part of its focus on super-specialty care in larger cities. Live Events Commenting on the growth levers, Soi said the biggest growth drivers today are the 'unsatiated' demand for quality healthcare and need for more capacity in the country, which will increase even further going ahead with an ageing population. 'Our sustained growth is a reflection of our strategy and execution capabilities,' said Soi. 'The commissioning of 160-bed brownfield tower at Max Mohali, along with additional brownfield capacities coming online at Max Smart and Nanavati-Max shortly, will significantly enhance clinical and financial performance of the network,' he added. 'In parallel, we are scaling up our clinical and support teams, while optimising our service mix to ensure rapid and effective utilisation of the new capacities,' he added. Going ahead the company will focus on a combination of brownfield and greenfield expansion to widen its network and meet the rising need for quality healthcare, said Soi. Shares of Max Healthcare Institute closed 0.44% up at Rs 1,267.60 apiece on the BSE on Wednesday. The company announced the earnings during market hours.
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Kalpataru posts Rs 49 crore loss in Q1 FY26 despite strong pre-sales
Mumbai-based real estate developer Kalpataru reported a widening of losses to Rs 49.43 crore in the first quarter of FY26, compared with Rs 0.69 crore in Q1 FY25. Revenue from operations stood at Rs 443.2 crore, down 16.45 per cent year-on-year (Y-o-Y), while total expenses fell 5.18 per cent Y-o-Y to Rs 512.23 crore. The company follows the project completion method (PCM) for recognising revenue from projects launched after April 2022. Under this method, revenue is recorded only upon receipt of the occupation certificate (OC), whereas expenses such as marketing and corporate overheads are booked in the same quarter they are incurred. As of Q1 FY26, the majority of recognised revenue came from projects under PCM. Of its 24 ongoing projects, Kalpataru applies PCM to 13; however, costs associated with these projects are fully charged to the profit and loss account during the reporting period. Pre-sales rose 83 per cent Y-o-Y to Rs 1,249 crore, while collections increased 37 per cent YoY to Rs 1,147 crore. However, the area sold fell 9 per cent Y-o-Y to 0.56 million square feet. Average sales realisation during the quarter surged 101 per cent Y-o-Y to Rs 22,476 per square foot. The company has guided pre-sales of Rs 7,000 crore for FY26, up from Rs 4,531 crore in FY25. It is targeting collections of Rs 5,700 crore, compared with Rs 3,659 crore in the previous financial year. Debt reduction focus Net debt as of June 30, 2025, stood at Rs 7,939 crore. The net debt-to-equity ratio improved to 2.0x from 3.8x as of March 31, 2025. Kalpataru aims to reduce its debt to Rs 7,300 crore by the end of FY26. 'The company has utilised Rs 1,192.5 crore from IPO proceeds towards debt repayment, in line with the objects of the issue, and remains committed to further strengthening the balance sheet through continued debt reduction efforts,' said Parag Munot, Managing Director, Kalpataru. On a sequential basis, revenue declined 26 per cent. The company had posted a profit of Rs 14.05 crore in Q4 FY25, compared with a loss in the current quarter. Kalpataru shares closed at Rs 406.30 on the BSE on Tuesday.
